ARS Pharmaceuticals vs Verastem
SPRY and VSTM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SPRY and VSTM compare
Verastem is the larger company, worth 2.0 times as much as ARS Pharmaceuticals ($764M against $379M).
ARS Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −164% compared with −178% at Verastem.
ARS Pharmaceuticals scores higher on the StockData Score (9 against 3 for Verastem), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SPRY | VSTM |
|---|---|---|
| Size and price | ||
| Market cap | $379M | $764M |
| Share price | $3.81 | $8.44 |
| Change, 1 year | −56.6% | −0.12% |
| Change, 5 years | −53.6% | −76.2% |
| Beta (5Y) | 1.43 | 1.37 |
| Employees | 158 | 102 |
| StockData Score | ||
| Total score | 9 (better) | 3 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.1× (better) | 7.6× |
| P/B | – | 75.7× |
| FCF yield | −48.3% | – |
| Growth | ||
| Revenue growth (TTM) | −14.5% | – |
| Revenue growth, 5Y average | – | −19.0% |
| Profitability | ||
| Operating margin | −161% (better) | −194% |
| Net margin | −164% (better) | −178% |
| FCF margin | −150% | – |
| Return on equity | −295% | – |
| Financial health | ||
| Interest coverage | – | −141.9× |
| Current ratio | 3.25 (better) | 1.93 |
| Altman Z-score | −3.07 (better) | −7.76 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 91.2% | 109% |
| Held by insiders | 46.7% | 1.8% |
| Insider net buying, 12 months | −$284K (better) | −$816K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 35.9% | 22.1% |
Go deeper
- SPRY stock overview
- SPRY income statement
- SPRY valuation and score
- VSTM stock overview
- VSTM income statement
- VSTM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.